Rani Therapeutics Holdings Inc (RANI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.87+1.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RANI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance the Phase 1 clinical trial of RT-114, an oral GLP-1/GLP-2 dual agonist for obesity treatment, targeting initiation by end of 2025.
Stated as a priority in 3 of last 3 quarters. Management has emphasized advancing and initiating the Phase 1 trial of RT-114 by end of 2025. Contract revenue increased from $0.2M in 2025-Q1 to $1.7M in 2026-Q1, reflecting collaboration progress. The trajectory shows delivering progress on this product development priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill for the treatment of obesity.”
“Looking ahead, we remain focused on initiating a Phase 1 trial for RT-114 by the end of 2025.”
“Initiation of Phase 1 clinical trial of RT-114 for the treatment of obesity expected in the second half of 2025.”
Maintain sufficient cash, cash equivalents, and marketable securities, including milestone payments, to fund operations through late 2027.
Stated as a priority in 3 of last 3 quarters. Cash, cash equivalents and marketable securities decreased from $49.7M in 2025-Q4 to $43.4M in 2026-Q1. Management expects these resources, including milestone payments, to fund operations into Q4 2027. The trajectory shows maintaining sufficient capital to support operations as stated.
“Cash, cash equivalents and marketable securities totaled $43.4 million; expected to fund operations into Q4 2027.”
“Cash, cash equivalents and marketable securities, including expected milestone payment, sufficient to fund operations into Q4 2027.”
“Rani expects cash and marketable securities, including milestone payment, to fund operations into Q4 2027.”
Appoint key executives and advisors to enhance strategic focus and technical leadership for pipeline prioritization and platform advancement.
Newly stated in 2026-Q1. Management announced appointments of key strategic and technical leaders to strengthen the leadership team. No direct financial metrics apply, but these hires support execution of stated priorities. Trajectory is newly initiated.
“Appointed Jesper Høiland as Head of Strategy and Dr. Sara Kenkare-Mitra as Strategic Advisor to advance platform and clinical strategy.”
Over the trailing year it converted 1.26x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
20 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.